INTRODUCTION
Hepatitis³ C³ virus³ (HCV)³ affects³ from³ 1.5%³ to³ 2.5%³ of³ the³ Western³ population,³ and³ is³ the³ most³ common³ source³ of³ infections³ transmitted³ by³ blood³ transfusions.³ HCV³ should³be³diagnosed³as³early³as³possible³as³ most³ patients³ without³ treatment³ develop³ hepatic³cirrhosis³and,³eventually,³hepatocel-lular³carcinoma. 1 
³
Interferon-α³ (IFN-α)³ is³ a³ good³ option³ for³ treating³ HCV.³ The³ antiviral³ action³ and³ modulatory³effect³of³the³drug³on³the³auto-immune³response³may³elicit³a³production³of³ antinuclear,³ antithyroid³ antibodies,³ as³ well³ as³ amplification³ of³ cellular³ cytotoxic³ response.³Treatment³using³IFN-α³and³ribavi-rin³(RBV),³a³synthetic³guanosine-nucleotide³ analog,³increased³remission³rates³from³20%³ to³40%.³The³therapeutic³efficacy³of³this³regi-men³can³be³explained³by³the³immunomod-ulatory³ and³ anti-inflammatory³ additional³ effects³of³RBV.³Hence,³this³combined³treat-ment³ favors³ the³ development³ of³ systemic³ and³ organ-specific³ autoimmune³ diseases,³ such³as³autoimmune³thyroid³disease³(ATD)³ and³thyroid³dysfunction³(TD). [2] [3] [4] Patients³infected³with³HCV³present³40-42%³of³detectable³antithyroid³autoantibody³ levels;³ whereas³ in³ patients³ with³ hepatitis³ B³ virus,³the³index³varies³from³5³to³10%. 4 ³The³ prevalence³ of³ TD³ in³ patients³ under³ IFN-α³ use ranges³ from³ 1³ to³ 35%,³ possibly³ due³ to³ the³ lack³ of³ standardization³ for³ the³ routine³ screening³of³thyroid³function³evaluation³in³ several³studies.³TD³resulting³from³the³use³of³ IFN-α³ presents³ a³ wide³ spectrum³ of³ forms³ and³ intensities,³such³as³thyrotoxicosis³in³2-3%³and³hypothyroidism³ in³ 2.4-19%³ of³ the³ cases. [4] [5] [6] ³ TD³ is³ frequently³ associated³ with³the³female³gender³and³HCV-related³factors. 7 ³There³ seems³to³be³no³correlation³between³TD³and³IFN-α³dosage;³ however,³ the³ duration³ of³ treatment³ may³ interfere.³ Additionally,³various³authors³have³reported³that³50%³of³ patients³with³HCV³and³antithyroperoxidase³antibodies³ detectable³prior³to³IFN-α³treatment³developed³ATD vs.³ 5.4%³of³patients³with³negative³antibodies. 5, 6 Considering³that³ATD³and³TD³occur³frequently³dur-ing³HCV³therapy³with³IFN-α³and³RBV,³there³is³a³recom-mendation³ of³ systematic³ evaluation³ for³ their³ presence³ during³treatment³and³follow-up.³Once³TD³is³diagnosed,³ very³often³the³treatment³for³HCV³is³unnecessarily³interrupted,³which³drastically³reduces³therapeutic³success. 6 The³ aim³ of³ the³ present³ study³ was³ to³ assess³ thyroid³ function³at³baseline³and³during³treatment³for³HCV³with³ standard³interferon-α³(IFN-α)³or³peguilated³interferon-α³ (PEG-IFN-α)³combined³with³RBV.
MATERIAL AND METHODS

Patients
We³prospectively³studied³293³patients³with³HCV,³treated³ with³ a³ combined³ regimen³ (IFN³ or³ PEG-IFN³ and³ RBV),³ and³they³were³followed³by³the³Infectious³Disease³Service³ between³2001³and³2007.³Other³etiologies³of³chronic³hepa-titis³were³excluded³and³no³patients³presented³hepatitis³B³ or³AIDS.
Thyroid³ function³ was³ evaluated³ in³ patients³ before³ treatment,³ every³ three³ months³ during³ treatment³ and³ six³months³after³treatment.³Patients³who³presented³TD³ at³ baseline³ underwent³ monthly³ reassessment;³ however,³ they³ were³ excluded³ from³ the³ follow-up³ group,³ com-prised³by³euthyroid³individuals.³The³patients³were³from³ the³city³Campinas³and³region,³state³of³São³Paulo,³an³io-dine³sufficient³area.³ 
Therapeutic plan
Statistical analysis
The³sample³profile³was³described³by³frequency³tables³of³ the³categorical³variables³(age,³gender,³qALT,³viral³genotype,³presence³of³cirrhosis,³liver³biopsy,³therapeutic³regimen,³type³of³INF-α³used,³total³treatment³time,³event³time³ during³treatment,³sustained³virological³response,³demon-strating³the³values³of³absolute³(n)³and³percentage³(%)³frequency.³ Continuous³ descriptive³ variables³ are³ presented³ as³ mean,³ standard³ deviation,³ minimum,³ maximum³ and³ median³values.³The³association³between³two³categorical³ variables³ was³ analyzed³ by³ either³ Chi-square³ or³ Fisher's³ test.³ The³ Mann-Whitney³ test³ was³ used³ to³ compare³ nu-merical³ variables³ between³ patients³ with³ and³ without³ thyroid³dysfunction.³The³significance³level³was³set³at³5%³ ³ (p³ <³ 0.05).³ Statistical³ analyses³ were³ performed³ using³ the³ SAS³system³for³Windows³(Statistical³Analysis³System)³ver-sion³8.02.³SAS³Institute³INC,³1999-2001,³Cary,³NC,³USA.
RESULTS
Out³of³293³patients³included³in³the³study,³we³verified³TD³ prior³to³the³use³of³IFN³in³20³(6.82%);³18³of³them³present-ed³ primary³ hypothyroidism³ (prevalence³ =³ 6.14%)³ and³ two,³ hyperthyroidism³ (prevalence³ =³ 0.68%)³ (Table³ 1).³ ³ Elevated³ serum³ TPOAb³ levels³ were³ detected³ in³ 13³ (5.46%),³and³TgAb³in³five³(1.68%)³of³238³patients.³ After³excluding³patients³with³previous³TD,³we³stud-ied³ 273³ euthyroid³ individuals³ who³ were³ treated³ with³ Interferon-α³ and³ ribavirin.³ Table³ 2³ describes³ the³ base-line³ characteristics³ of³ the³ euthyroid³ study³ patients³ prior³to³treatment.³Under³treatment,³19%³(n³=³52)³de-veloped³ TD,³ 18%³ of³ the³ men³ and³ 27%³ of³ the³ women³ ³ (p³ =³ 0.104).³ TD³ was³ diagnosed 25.8³ ±³ 15.5³ weeks³ ³ after³treatment³initiation.³Hypothyroidism³was³verified³ ³ in³17.2%³(n³=³47);³hyperthyroidism³in³1.8%³(n³=³5),³and³ ³ 5.1%³(n³=³14)³presented³destructive³thyroiditis³(DT).³ 
Virus³C³genotype³predisposes³to³primary³hypothyroidism
DISCUSSION
Hepatitis³C³virus³is³a³hepatotropic³and³lymphotropic³RNA³ virus³which³may³be³associated³with³chronic³infectious³disease. 8 ³Although³hepatocytes³are³the³major³site³of³HCV³replication,³extrahepatic³complications³of³HCV³infection³may³ occur,³ such³ as³ autoimmune³ diseases³ and³ lymphoprolifera-tive³disorders. 9 HCV³treatment³with³IFN-α³and³RBV³can³trigger³adverse³ efects³ frequently³ leading³ to³ a³ reduction³ of³ the³ dose³ in³ over³ 40%³of³the³patients³or³even³withdrawal³in³approximately³14%. 8 Standard³ or³ PEG-IFN-α³ may³ lead³ to³ inluenza-like³ symptoms³at³the³onset³of³treatment,³as³well³as³psychiatric,³ hematologic³ (neutropenia³ and³ thrombocytopenia) 10,11 ³ and³ thyroid³dysfunction. 12 ³As³referred³by³Sachithanandan³et³al., 13 ³ thyropathies³afect³26.3%³of³HCV³treated³patients.³he³as-sociation³with³RBV³usually³induces³hemolytic³anemia,³with³ no³additional³risk³of³thyropathy. 10 Generally,³ SVR is³ achieved³ in³ approximately³ 60%³ of³ the³patients,³40%³among³patients³of³viral³genotype³1³and³ 76%³among³those³with³viral³genotypes³2³and³3.³Other³SVR³ predictive³factors³include:³age³less³than³40³years,³weight³ lower³than³75³kg,³female³gender,³Caucasian³race,³low³vi-ral³load³before³treatment,³and³absence³of³liver³cirrhosis. 10 ³ In³ our³ study,³ HCV³ patients³ obtained³ 53.9%³ as³ response³ rate³of³IFN-α³therapy,³in³accordance³to³the³literature.³The³ study³ population³ showed³ a³ predominance³ of³ Caucasoid³ male³patients³infected³by³virus³C³of³genotypes³1³and³3. Based³on³the³literature, 2 ³standard³IFN³was³indicated³ for³ patients³ infected³ with³ virus³ of³ genotypes³ 2³ and³ 3,³ and³PEG-IFN³was³the³first³choice³for³genotype³1.³Non-responding³patients³with³genotypes³2³and³3³could³then³ be³ treated³ with³ PEG-IFN.³ More³ than³ one³ therapeutic³ regimen³ was³ prescribed³ to³ 35.2%³ of³ the³ patients,³ and³ 54.8%³ of³ them³ were³ treated³ for³ 48³ weeks.³ PEG-IFN³ was³ administrated³ to³ 165³ patients:³ those³ who³ weighed³ less³ than³ 75³ kg³ used³ PEG-IFN-α³ 2b³ and³ those³ with³ ³ more³than³75³kg,³PEG-IFN-α³2a.³ Firstly,³Pateron³et³al. 14 ³reported³a³prevalence³of³14%³of³ ³ antithyroid³ autoantibodies³ in³ HCV³ patients.³ A³ review³ ³ of³published³controlled³studies 15 ³observed³that³most³reports³ conirmed³a³higher³prevalence³of³autoimmune³thyroid³dis-ease³and³hypothyroidism³in³chronic³HCV-infected³patients.³ Several³studies³found³that³female³gender³and³the³pres-ence³of³TPOAb³were³considered³major³risk³factors³for³the³ development³of³hypothyroidism. [16] [17] [18] [19] ³Our³data³demonstrated³ that³ TPOAb-positive³ patients³ had³ a³ higher³ chance³ of³ de-veloping³hypothyroidism;³however,³females³were³not³more³ prone,³similarly³to³the³indings³reported³by³Muratori³et³al. 20³ and³Stefanova-Petrova³et³al. 21³ he³ prevalence³ of³ hypothyroidism³ in³ HCV³ patients³ is³ approximately³9%³(0-13%)³vs.³3%³(0.5-4%)³in³healthy³subjects. 19 ,22-24 ³hyroid³autoimmunity³was³demonstrated³in³15%³ (5-28%)³of³the³HCV³patients³and³in³12%³(0-11%)³of³healthy³ subjects,³ indicating³ a³ slight³ though³ signiicantly³ higher³ risk. 15 ³In³our³study,³we³veriied³that³the³prevalence³of³hypo-thyroidism³(6.1%)³and³thyroid³autoimmunity³(5.5%)³found³ in³HCV³patients³before³treatment³was³similar³to³the³litera-ture³reports,³in³spite³of³the³diferences³existing³in³geographi-cal³ distribution,³ genetic³ variability,³ iodine³ intake³ or³ other³ infectious³agents. 25, 26 ³Moreover,³the³prevalence³of³hyperthy-roidism³before³IFN-α³treatment³(0.68%)³found³in³our³study³ population³was³not³signiicantly³diferent³in³HCV-infected³ patients,³as³described³in³the³literature. 15 Ater³IFN-α³therapy,³19%³presented³thyroid³dysfunction:³ hypothyroidism³ in³ 17.2%,³ hyperthyroidism³ in³ 1.8%³ and³ destructive³ thyroiditis³ in³ 5.1%³ -³ very³ similar³ values³ were³ found³by³Sachithanandan³et³al. 13 ³(26.3%),³higher³than³those³ described³by³Moncoucy³et³al. 27 ³(7%)³and³Tran³et³al. 16 ³(6.7%).³ he³ rates³ of³ thyroid³ dysfunction³ triggered³ by³ the³ two³ types³ of³ IFN-α,³ standard³ and³ peguilated,³ were³ similar,³ as³ also³found³by³Moncoucy³et³al. 27 ³Moreover,³thyroid³dysfunc-tion³was³not³associated³with³sustained³virological³response³ of³chronic³hepatitis³C³to³IFN-α³therapy,³as³also³demonstrat-ed³by³Hsieh³et³al. 28 ³and³in³contrast³to³previous³reports. 29-31³ In³our³patients,³the³presence³of³thyroid³dysfunction³did³not³ lead³to³changes³in³the³dose³or³therapy³withdrawal.
Ater³ IFN-α³ plus³ RBV³ treatment³ 17.2%³ developed³ pri-mary³hypothyroidism.³However,³this³rate³has³varied³in³sev-eral³ studies. 16, 27 ³ Among³ risk³ factors³ evaluated:³ age,³ gender,³ presence³of³cirrhosis,³qALT³and³FT 4 ³levels³before³treatment,³ type³and³commercial³presentation³of³IFN-α³used,³and³SVR,³ we³ found³ no³ association³ with³ primary³ hypothyroidism.³ In³ contrast,³the³likelihood³of³developing³primary³hypothyroid-ism³increased³in³the³presence³of³TPOAb,³genotype³1,³to³be³ on³the³irst³therapeutic³regimen,³and³having³higher³TSH³lev-els³before³treatment.³his³last³inding³was³also³observed³by³ Antonelli³et³al. 19³ Detection³ of³ TPOAb³ before³ therapy³ was³ associated³ with³a³risk³3.5³times³greater³of³becoming³hypothyroid³on³ IFN-α³use;³90%³of³such³patients³in³our³study³developed³ the³dysfunction³vs.³14.5%³of³TPOAb-negative,³corrobo-rating³Prummel³and³Laurberg, 7 ³who³found³a³relative³risk³ of³ 3.9.³ Elevated³ endogenous³ interferon³ in³ response³ to³ viral³ diseases³ could³ possibly³ be³ associated³ with³ the³ de-velopment³of³IFN-α³induced³thyroiditis³by³in³genetically³ predisposed³individuals. 17, 27, [32] [33] [34] Prummel³ and³ Laurberg 7 ³ have³ demonstrated³ that³ the³ female³gender³has³a³relative³risk³of³4.4³for³developing³au-toimmune³ thyroiditis.³ This³ strong³ preponderance³ may³ perhaps³be³due³to³the³effects³of³estrogen³or³secondary³to³ X³chromosome³susceptibility³genes. 35, 36 ³This³fact³was³not³ corroborated³by³our³study,³as³well³as³by³Muratori³et³al. 20 ³ and³Stefanova-Petrova³et³al. 21 ³It³is³important³to³highlight³ that³thyroid³dysfunction³could³result³from³a³direct³effect³ of³IFN-α³on³thyroid³cell³function. 28, 37, 38 he³higher³prevalence³of³virus³C³genotype³1³in³patients³ who³developed³hypothyroidism³is³not³a³consensus³in³the³ literature.³ Sachithanandan³ et³ al. 13 ³ have³ detected³ elevated³ TPOAb³ levels³ before³ and³ during³ therapy³ only³ in³ geno-type³1³patients.³Conversely,³Huang³et³al. 34 ³observed³higher³ prevalence³of³genotype³1b/2b³in³women³with³hepatitis³C³ and³detectable³TPOAb,³but³with³no³correlation³with³hypothyroidism.³ Viral³ replication³ results³ in³ the³ production³ of³ a³heterogeneous³viral³population³within³an³infected³individual. 39 ³Some³authors³suggested³that³a³portion³of³the³HCV³ genome³could³share³a³partial³sequence³homology³in³a³few³ amino³acid³segments³with³thyroglobulin³and³microsome,³ rendering³ HCV³ patients³ susceptible³ to³ autoimmune³ thy-roid³diseases. 28 43 ³ Our³ data³ did³ not³ suggest³ a³ cumulative³ dose-effect,³ as³ only³ a³ few³ patients³ did³ not³ present³ thyroid³ dysfunction³ during³ the³ first³ treatment.³ Interestingly,³after³drug³withdrawal,³64%³of³the³patients³ remained³hypothyroid,³requiring³L-thyroxin³replacement³ therapy,³and³the³other³patients³presented³the³subclinical³ form³of³the³disease.
Hyperthyroidism³seems³a³rare³event³during³IFN-α³ther-apy³and³was³veriied³in³1.8%³of³the³patients.³Several³studies³ found³ even³ lower³ prevalence³ of³ hyperthyroidism,³ ranging³ from³0.9%³to³1.1%. 16, 27, 29, 44 Destructive³thyroiditis³occurred³in³5.1%³of³our³patients³ and³approximately³70%³developed³permanent³hypothyroidism.³Almost³50%³of³non-autoimmune³IFN-α-induced³thy-roiditis³manifests³such³a³destructive³thyroiditis,³a³self-lim-ited³inlammatory³disorder³characterized³by³three³phases³of³ six³to³eight³weeks³each:³thyrotoxicosis,³hypothyroidism³and³ resolution³to³euthyroidism³or³deinitive³hypothyroidism³in³ less³ than³ 5%³ of³ the³ cases.³ he³ symptoms³ are³ usually³ mild,³ probably³leading³to³a³lower³diagnostic³rate;³however,³atrial³ ibrillation³may³occur. 8, 45 ³We³observed³that³TSH³levels³before³ treatment³were³higher³and³qALT³was³lower³in³patients³who³ developed³destructive³thyroiditis³under³IFN-α.³his³inding³ has³not³been³previously³reported³in³the³literature.³Some³au-thors³found³recurrent³thyroiditis³during³retreatment; 46 ³however,³in³our³study,³98%³of³the³patients³developed³destructive³ thyroiditis³only³during³the³irst³treatment.
We³concluded³that³in³the³screening³for³predictive³factors³ of³ thyroid³ dysfunction³ in³ HCV³ patients³ before³ treatment³ with³IFN-α³it³is³especially³important³to³evaluate³TSH³levels,³ as³well³as³antithyroid³antibodies³and³viral³genotype.³Moreover,³ the³ irst³ contact³ with³ IFN-α³ holds³ substantial³ risk³ to³ develop³thyroid³dysfunction.³Special³care³is³essential³when³ there³ are³ laboratory³ alterations³ indicating³ thyrotoxicosis,³ which³may³be³signaling³an³initial³phase³of³destructive³thyroiditis,³a³benign³and³self-limited³disturbance.³We³empha-size³that³a³signiicant³part³of³the³dysfunction³was³transient³ or³subclinical,³not³requiring³treatment.³
